NCT05914428

Biomarkers to Predict Acute Respiratory Distress Syndrome(ARDS) in Patients With Sepsis

Status unknown Last updated 22 June 2023

What this trial tests

trial testing ALDH2 rs671 mutation in Sepsis in 170 participants. Status unknown.

Timeline

13 June 2023

Primary endpoint
15 July 2023

15 July 2023

Quick facts

Lead sponsor	Qilu Hospital of Shandong University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	170
Start date	13 June 2023
Primary completion	15 July 2023
Estimated completion	15 July 2023
Sites	1 location across China

Drugs / interventions tested

• ALDH2 rs671 mutation

Conditions studied

• Sepsis — all drugs for Sepsis →

Sponsor

Qilu Hospital of Shandong University

Who can join

Adults 18 to 85, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sepsis-induced acute respiratory distress syndrome (ARDS) is a life-threatening acute inflammatory lung injury, associated with increased pulmonary microvascular permeability, increased lung weight, and loss of aerated lung tissue.Despite advances in critical care, no established and targeted treatment for ARDS, contributing to a persistently high mortality rate of 34% to 45%. Therefore, exploring novel therapeutic targets for septic ARDS is of paramount importance.Acetaldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme that serves as the primary toxic aldehyde scavenger and is expressed in various cells, including neutrophils. The ALDH2 rs671 single nucleotide polymorphism, leading to an approximate 90% decrease in ALDH2 enzymatic activity, is implicated in occurrence of macrovascular conditions, such as coronary artery disease, pulmonary arterial hypertension, and aortic aneurysm or dissection.An array of studies has delved into role of ALDH2 in regulating cellular processes, including inflammation, autophagy, apoptosis, necrosis,efferocytosis and pyroptosis.but whether it associated with the incidence of septic-ARDS remains unknown.The aim of this study was to determine whether the ALDH2 rs671 single nucleotide polymorphism was associated with the incidence of septic-ARDS.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Exploring the role of pyroptosis in the pathogenicity of heart disease.
   Bhatti R, Sato PY. · · 2024 · cited 7× · PMID 38645692 · DOI 10.3389/fphys.2024.1357285